

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | — | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
| Drug common name | ONAMETOSTAT |
| INN | onametostat |
| Description | Onametostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target protein arginine N-methyltransferase 5. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc2cc(CC[C@H]3C[C@@H](n4ccc5c(N)ncnc54)[C@H](O)[C@@H]3O)ccc2cc1Br |
| PDB | — |
| CAS-ID | 2086772-26-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4249337 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | N8VKI8FPW0 (ChemIDplus, GSRS) |
